Purepac gains permission to add to etodolac line

Drug Store News, June 22, 1998

International pharmaceutical and healthcare company F. H. Faulding & Co. Ltd. recently announced that its wholly owned subsidiary, Purepac Pharmaceutical Co., has received clearance from the Food and Drug Administration to manufacture and market etodolac 500mg

Richard F. Moldin, chief executive officer of Faulding Oral pharmaceuticals, said, "Our 500 mg etodolac tablets are the generic equivalent of Wyeth-Ayerst Laboratories Lodine(r) brand 500 mg tablets, indicated for acute and long-term use in the management of osteoarthritis and pain. It is an extension of our existing etodolac product line, which already includes etodolac 400 mg tablets, which have been marketed since March 1997." Brand sales for etodolac 500 mg tablets are estimated to be in excess of $45 million for the past 12 months. Purepac will commence commercial immediately.

Faulding Oral Pharmaceuticals develops, manufactures and markets human pharmaceuticals medical devices.

For more information, call (908) 527-9100.